The National Law Review has published "How MoCRA Is Reshaping FDA Oversight of Cosmetics in 2026," a new analysis framing 2026 as the next regulatory inflection point for the US personal care industry under the Modernization of Cosmetics Regulation Act.

The piece targets formulators, regulatory affairs teams, brand owners and procurement leads, signalling that compliance workload tied to MoCRA will intensify rather than ease over the next twelve months. The headline framing — "reshaping" — implies the law is moving from initial implementation into the more operationally consequential provisions that affect manufacturing, documentation and disclosure.

What does the 2026 phase of MoCRA change for industry?

MoCRA, enacted in December 2022, marked the first substantive US federal overhaul of cosmetic regulation in more than 80 years. The earliest compliance deadlines on facility registration and product listing are now behind the industry.

The 2026 horizon identified in the National Law Review analysis points to the next, more operationally heavy tranche of FDA obligations — most notably the finalization of pending rulemakings and the rollout of disclosure requirements that touch formulation, labelling and supplier documentation.

Where will compliance workload concentrate?

For compliance leads, the practical signal is that the US federal floor is rising while state-level requirements in markets including California and New York continue to layer on top. Multi-jurisdictional brands already running parallel US-EU dossiers will need to expand them; independent brands without in-house regulatory staff face the steepest learning curve.

For contract manufacturers, the implications cut deeper. Brand owners are likely to push MoCRA documentation requirements into master service agreements and quality contracts, meaning CMO relationships without explicit MoCRA alignment will be exposed through 2026.

What should compliance and formulation teams track?

Three workstreams warrant close attention heading into 2026:

• Manufacturing standards: any final Good Manufacturing Practice rule will dictate documentation, recordkeeping and facility controls across the contract manufacturing base.
• Disclosure obligations: expanded labelling or allergen reporting — depending on the final shape of FDA rulemaking — will require fragrance houses and finished-goods brands to update ingredient declarations.
• Post-market surveillance: adverse event reporting and the framework around it remain operational priorities that affect brand safety teams and contract manufacturers.

How should R&D and procurement teams respond?

R&D directors should expect ingredient dossiers and safety substantiation files to expand as FDA guidance matures. Procurement teams can expect supplier RFPs to call out MoCRA-compliant documentation more frequently, particularly for actives, botanicals and ingredients where traceability concerns dominate. Independent beauty brands operating without in-house regulatory staff face the steepest adoption curve.

Raw material suppliers with global footprints will feel the squeeze from both sides: EU buyers already require REACH-grade documentation, and US brand owners are now adding MoCRA-aligned paperwork on top.

What does this mean for multi-jurisdictional brands?

Brands running parallel US-EU compliance systems already manage a higher documentation baseline. The National Law Review piece suggests the US side is catching up. Watch for harmonization pressure on fragrance allergens, where US practice has historically lagged EU listing requirements, and for any federal allergen updates that trigger finished-product relabel cycles.

What to watch next

The most consequential 2026 milestone is the publication of FDA's final Good Manufacturing Practice rule. Brand owners should also track guidance on allergen disclosure, the rollout of safety substantiation expectations and any first deployment of FDA's mandatory recall authority — each will reset the US regulatory benchmark heading into 2027.